---
id: immunocompromised-host-infections_114
category: special-populations
tags: [immunocompromised, opportunistic-infections, immunosuppression, defects]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Infections in the Immunocompromised Host

**Q:** What are the types of immunodeficiency, associated infections by defect type, and approach to fever in immunocompromised patients?

**A:**

## TYPES OF IMMUNODEFICIENCY

| **Defect Type** | **Causes** | **Key Infections** |
|-----------------|------------|-------------------|
| **Neutropenia** | Chemotherapy, aplastic anemia, leukemia | **Bacteria** (Gram-negative, Gram-positive)<br>**Fungi** (Candida, Aspergillus) |
| **Cell-Mediated Immunity (T-cell)** | HIV, steroids, biologics (anti-TNF), transplant | **Intracellular pathogens:**<br>**PCP, Toxoplasma, Cryptococcus, Nocardia, Listeria, Mycobacteria, CMV, VZV** |
| **Humoral Immunity (B-cell)** | CLL, multiple myeloma, rituximab, CVID | **Encapsulated bacteria:**<br>**S. pneumoniae, H. influenzae, N. meningitidis** |
| **Complement Deficiency** | C5-C9 deficiency, eculizumab, SLE | **N. meningitidis** (recurrent) |
| **Asplenia** | Splenectomy, sickle cell disease | **Encapsulated bacteria:**<br>**S. pneumoniae, H. influenzae, N. meningitidis**<br>**Babesia, Capnocytophaga** (dog bites) |

**Key Point:** **Match the immune defect to the infection risk**

---

## INFECTIONS BY IMMUNE DEFECT

### **1. NEUTROPENIA (ANC <500 cells/μL)**

**High-Risk Bacteria:**
- **Gram-negative:** *E. coli, Klebsiella, Pseudomonas aeruginosa*
- **Gram-positive:** *Staph aureus, CoNS, Viridans streptococci*

**High-Risk Fungi:**
- **Candida** (especially if prolonged neutropenia >7 days)
- **Aspergillus** (if >10-14 days)

**Key Point:** **Prolonged neutropenia (>7 days) → invasive fungal infections**

---

### **2. CELL-MEDIATED IMMUNITY DEFECTS (T-cell)**

**Mnemonic: "Intracellular PaThOGeNs LiVe iN Cells"**

| **Pathogen** | **Key Clinical Syndrome** |
|--------------|---------------------------|
| **PCP** (Pneumocystis jirovecii) | Pneumonia (CD4 <200) |
| **Toxoplasma** | CNS abscess (CD4 <100) |
| **Cryptococcus** | Meningitis (CD4 <100) |
| **Nocardia** | Lung abscess, brain abscess |
| **Listeria** | Meningitis, bacteremia |
| **Mycobacteria** (TB, MAC) | Disseminated TB, MAC (CD4 <50) |
| **CMV** | Retinitis, colitis, esophagitis (CD4 <50) |
| **VZV** | Disseminated zoster |
| **Strongyloides** | Hyperinfection syndrome (steroids) |

**Key Point:** **Steroids → Strongyloides hyperinfection, PCP, disseminated fungi**

---

### **3. HUMORAL IMMUNITY DEFECTS (B-cell)**

**High-Risk Bacteria:**
- **Encapsulated organisms:**
  - **S. pneumoniae** (#1 risk)
  - **H. influenzae**
  - **N. meningitidis**

**Clinical Syndromes:**
- **Recurrent sinopulmonary infections**
- **Invasive pneumococcal disease** (bacteremia, meningitis)

**Key Point:** **Encapsulated bacteria = polysaccharide capsule (requires antibody for opsonization)**

---

### **4. COMPLEMENT DEFICIENCY**

**C5-C9 (Terminal Complement Deficiency):**
- **N. meningitidis** (recurrent, invasive disease)

**Eculizumab (C5 inhibitor):**
- **N. meningitidis** (20-40x increased risk)
- **Prophylaxis:** Meningococcal vaccine + **penicillin prophylaxis** or close monitoring

**Key Point:** **Complement deficiency = recurrent Neisseria infections**

---

### **5. ASPLENIA / HYPOSPLENIA**

**High-Risk Bacteria:**
- **S. pneumoniae** (#1 - 50% of overwhelming post-splenectomy infection)
- **H. influenzae type b**
- **N. meningitidis**
- **Capnocytophaga canimorsus** (dog bites - can cause fulminant sepsis)

**High-Risk Parasites:**
- **Babesia microti** (babesiosis)

**Prevention:**
- **Vaccinate:** PCV20/PPSV23, Hib, MenACWY, MenB
- **Prophylactic antibiotics:** **Penicillin VK** 250-500 mg PO BID OR **amoxicillin** 250 mg PO daily (lifelong in children, ≥2 years in adults)

**Key Point:** **Asplenia = encapsulated bacteria (OPSI = overwhelming post-splenectomy infection)**

---

## APPROACH TO FEVER IN IMMUNOCOMPROMISED HOST

### **Step 1: Assess Immune Defect Type**

| **Clinical Clue** | **Defect Type** |
|-------------------|-----------------|
| **Chemotherapy, ANC <500** | Neutropenia |
| **HIV (CD4 <200), steroids, biologics** | T-cell defect |
| **CLL, rituximab, CVID** | B-cell defect |
| **Splenectomy, sickle cell disease** | Asplenia |
| **Eculizumab** | Complement deficiency |

---

### **Step 2: Broad Empiric Coverage**

**Neutropenic Fever:**
- **Cefepime** 2g IV q8h OR **Piperacillin-tazobactam** 4.5g IV q6h
- **Add vancomycin** if suspected MRSA, line infection, or hemodynamic instability
- **Consider antifungal** if fever >4-7 days (micafungin, voriconazole)

**T-cell Defect:**
- **TMP-SMX** (PCP)
- **Acyclovir** (HSV/VZV)
- Consider **Toxoplasma, Cryptococcus, Nocardia** (CT head if CNS symptoms)

**Asplenia (Severe Sepsis/Shock):**
- **Ceftriaxone** 2g IV q24h + **Vancomycin** (covers S. pneumoniae, including PRSP)

---

### **Step 3: Targeted Diagnostics**

**Neutropenic Fever:**
- Blood cultures (peripheral + line if present)
- CXR
- Consider **CT chest** if persistent fever (invasive fungal infection)
- **Serum galactomannan, beta-D-glucan** (if prolonged fever/neutropenia)

**T-cell Defect:**
- CD4 count (if HIV suspected)
- **Serum cryptococcal antigen**
- **CT chest** (PCP vs fungal)
- **CT head with contrast** (Toxoplasma vs CNS lymphoma vs Cryptococcus)
- **CMV PCR** (blood)

**Asplenia:**
- Blood cultures
- Blood smear (Babesia - intraerythrocytic parasites)

---

## PROPHYLAXIS BY IMMUNE DEFECT

| **Defect** | **Prophylaxis** | **Indication** |
|------------|-----------------|----------------|
| **HIV (CD4 <200)** | **TMP-SMX 1 DS daily** | PCP + Toxoplasma prophylaxis |
| **HIV (CD4 <50)** | **Azithromycin 1200 mg weekly** | MAC prophylaxis |
| **Neutropenia (prolonged)** | **Fluoroquinolone** (levofloxacin 500 mg daily) | High-risk (AML, HSCT) |
| **Asplenia** | **Penicillin VK 250-500 mg BID** | Encapsulated bacteria |
| **Eculizumab** | **Penicillin** OR close monitoring | N. meningitidis |
| **Steroids (high-dose)** | **TMP-SMX 1 DS 3x/week** | PCP prophylaxis |
| **Solid organ transplant** | **Valganciclovir** | CMV prophylaxis (donor+/recipient-) |

**Key Point:** **TMP-SMX = PCP + Toxoplasma prophylaxis** (dual coverage)

---

## SPECIFIC SYNDROMES IN IMMUNOCOMPROMISED HOSTS

**STRONGYLOIDES HYPERINFECTION SYNDROME:**
- **Risk:** High-dose steroids, HTLV-1 infection
- **Clinical:** Gram-negative bacteremia/meningitis (larvae carry GI flora)
- **Treatment:** **Ivermectin** 200 μg/kg/day x 2 days (repeat if severe)
- **Screening:** Strongyloides serology before starting immunosuppression (endemic areas)

**PCP PNEUMONIA:**
- **Risk:** CD4 <200, steroids (≥20 mg prednisone x ≥1 month)
- **Clinical:** Subacute dyspnea, hypoxemia, bilateral interstitial infiltrates
- **Treatment:** **TMP-SMX** 15-20 mg/kg/day (TMP component) ÷ TID-QID x 21 days + **prednisone** (if PaO₂ <70 mmHg)

**INVASIVE ASPERGILLOSIS:**
- **Risk:** Prolonged neutropenia (>10 days), HSCT, high-dose steroids
- **Clinical:** Fever unresponsive to antibiotics, **angioinvasion** (tissue necrosis), pulmonary nodules with **halo sign**
- **Treatment:** **Voriconazole** 6 mg/kg IV q12h x 2 → 4 mg/kg IV q12h

---

**Clinical Pearls:**
- **Match immune defect to infection risk** (neutropenia → bacteria/fungi, T-cell → intracellular, B-cell → encapsulated)
- **Neutropenia >7 days → invasive fungal infections** (Candida, Aspergillus)
- **Steroids → PCP, Strongyloides, disseminated fungi**
- **Asplenia → encapsulated bacteria** (S. pneumoniae, H. influenzae, N. meningitidis, Capnocytophaga)
- **TMP-SMX = PCP + Toxo prophylaxis** (start if CD4 <200)
- **Screen for Strongyloides before starting immunosuppression** (endemic areas)
- **Eculizumab → N. meningitidis** (vaccinate + penicillin prophylaxis)

**Media:** None

**Sources:** [IDSA 2024 - Immunocompromised host infections], [AST 2024 - Transplant infections]
